Unknown

Dataset Information

0

Targeting the IL-6/JAK/STAT3 signalling axis in cancer.


ABSTRACT: The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In the tumour microenvironment, IL-6/JAK/STAT3 signalling acts to drive the proliferation, survival, invasiveness, and metastasis of tumour cells, while strongly suppressing the antitumour immune response. Thus, treatments that target the IL-6/JAK/STAT3 pathway in patients with cancer are poised to provide therapeutic benefit by directly inhibiting tumour cell growth and by stimulating antitumour immunity. Agents targeting IL-6, the IL-6 receptor, or JAKs have already received FDA approval for the treatment of inflammatory conditions or myeloproliferative neoplasms and for the management of certain adverse effects of chimeric antigen receptor T cells, and are being further evaluated in patients with haematopoietic malignancies and in those with solid tumours. Novel inhibitors of the IL-6/JAK/STAT3 pathway, including STAT3-selective inhibitors, are currently in development. Herein, we review the role of IL-6/JAK/STAT3 signalling in the tumour microenvironment and the status of preclinical and clinical investigations of agents targeting this pathway. We also discuss the potential of combining IL-6/JAK/STAT3 inhibitors with currently approved therapeutic agents directed against immune-checkpoint inhibitors.

SUBMITTER: Johnson DE 

PROVIDER: S-EPMC5858971 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Johnson Daniel E DE   O'Keefe Rachel A RA   Grandis Jennifer R JR  

Nature reviews. Clinical oncology 20180206 4


The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In the tumour microenvironment, IL-6/JAK/STAT3 signalling acts to drive the proliferation, survival, invasiveness, and metastasis of tumour cells, while strongly suppressing the antitumour immune response. Thus, treatments that target the IL-6/JAK/STAT3 pathway in patients with cancer are poised to provide therapeutic benefit by directl  ...[more]

Similar Datasets

| S-EPMC5974310 | biostudies-literature
| S-EPMC6333970 | biostudies-literature
| S-EPMC8778669 | biostudies-literature
| S-EPMC8964978 | biostudies-literature
| S-EPMC6608985 | biostudies-literature
| S-EPMC8036560 | biostudies-literature
| S-EPMC5099878 | biostudies-other
| S-EPMC6680233 | biostudies-literature
2021-03-26 | GSE112350 | GEO
| S-EPMC3492731 | biostudies-literature